NASDAQ: RKDAArcadia Biosciences Inc Stock
$7.47+0.13 (+1.77%)
Updated Mar 24, 2023
RKDA Price
$7.47
Fair Value Price
$44.48
Market Cap
$4.60M
52 Week Low
$6.69
52 Week High
$88.00
P/E
-0.2x
P/B
0.18x
P/S
1.17x
PEG
N/A
Dividend Yield
N/A
Revenue
$11.13M
Earnings
-$20.41M
Gross Margin
-7.9%
Operating Margin
-184.59%
Profit Margin
-183.5%
Debt to Equity
0.38
Operating Cash Flow
-$18M
Beta
0.84
Next Earnings
Mar 30, 2023
Ex-Dividend
N/A
Next Dividend
N/A
RKDA Overview
Arcadia Biosciences, Inc. produces and markets plant-based health and wellness products in the United States. It engages in developing crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health and wellness products, and their viability for industrial applications. The company was incorporated in 2002 and is headquartered in Davis, California.
Zen Score
–
Industry Average (35)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how RKDA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RKDA ($7.47) is undervalued by 83.21% relative to our estimate of its Fair Value price of $44.48 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
RKDA ($7.47) is significantly undervalued by 83.21% relative to our estimate of its Fair Value price of $44.48 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
RKDA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more RKDA due diligence checks available for Premium users.
Be the first to know about important RKDA news, forecast changes, insider trades & much more!
RKDA News
Valuation
RKDA fair value
Fair Value of RKDA stock based on Discounted Cash Flow (DCF)
Price
$7.47
Fair Value
$44.48
Undervalued by
83.21%
RKDA ($7.47) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RKDA ($7.47) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RKDA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
RKDA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.2x
Industry
15.23x
Market
21.37x
RKDA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.18x
Industry
1.7x
RKDA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RKDA's financial health
Profit margin
Revenue
$1.9M
Net Income
-$2.9M
Profit Margin
-152.7%
RKDA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
RKDA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$34.5M
Liabilities
$9.5M
Debt to equity
0.38
RKDA's short-term assets ($30.03M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RKDA's short-term assets ($30.03M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RKDA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RKDA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.4M
Investing
$341.0k
Financing
$4.5M
RKDA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RKDA vs Agricultural Input Stocks
Arcadia Biosciences Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.